Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Neoadjuvant Therapy in TNBC
NCT02489448Phase 2Completed
- Sponsor
- Yale University
- Start
- Nov 2015
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in triple-negative breast cancer (TNBC), sponsored by Yale University. Started Nov 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02489448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02489448.